Zanubrutinib then sonrotoclax combo for new CLL/SLL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests two targeted drugs: zanubrutinib followed by a combination with sonrotoclax for people with newly diagnosed CLL or SLL who need treatment for the first time. The goal is to see if a limited-duration, fixed-course treatment can control the disease effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have been newly diagnosed with CLL or SLL.
- You need to have at least one sign that treatment is needed, such as anemia, low platelets, big lymph nodes, or symptoms like weight loss or fever.
- You cannot have had any prior treatment for CLL/SLL (this is the first treatment).
- Your organs, especially liver and kidneys, must be working well enough (within specific blood test limits).
- You must be willing to use effective birth control during and for 4 weeks after the study.
- You cannot have other serious health conditions like uncontrolled infections, heart problems, or a history of certain cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (sonrotoclax and zanubrutinib) for people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who need treatment. It aims to see if using these drugs early can help achieve better deep responses.
This trial tests whether adding a new drug, sonrotoclax, to the standard treatment zanubrutinib works better for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It's for patients aged 65 and older who need therapy due to symptoms or blood cell issues.
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
This trial tests a combination of two targeted drugs (zanubrutinib and sonrotoclax) as a first treatment for people with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). It aims to see if this approach works better than standard care by using a test called MRD to guide treatment duration.
This trial tests a combination of two targeted drugs, zanubrutinib (a pill) and obinutuzumab (an infusion), for people with untreated CLL or SLL who need treatment. The goal is to see if this combination works well and is safe.
This trial tests a combination of three drugs (sonrotoclax, rituximab, and zanubrutinib) for people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or mantle cell lymphoma. The goal is to see if the combination works better than current treatments.
Hear when a new CLL/SLL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.